Mohammed T Syed

US Patent:

20070282673, Dec 6, 2007

Filed:

Apr 30, 2007

Appl. No.:

11/796918

Inventors:

Ajay Nagpal - Short Hills NJ, US
Ken Umezaki - New York NY, US
Roben Dunkin - Glen Ridge NJ, US
Vinod Vallabhaneni - Hoboken NJ, US
Yuriy Chernyshenko - Staten Island NY, US
Terry Leung - Edison NJ, US
Mohammed Syed - Jersey City NJ, US

Assignee:

Lehman Brothers Inc. - New York NY

International Classification:

G06Q 10/00
G06F 17/18
G06F 3/14

US Classification:

705011000, 715700000

Abstract:

The present invention is directed to a system and method for displaying sales information to a sales person via a portal. Data from a plurality of data sources is aggregated. Sales credit information attributable to the sales person for his clients, and for products associated with one or more of such clients, is identified. Based on (i) user profile information for the sales person, (ii) at least some of the aggregated data, and (iii) at least some of the identified sales credit information, sales strategy information is generated for the sales person. Content of the portal is generated based on the sales strategy information.

US Patent:

20230000824, Jan 5, 2023

Filed:

Jul 6, 2022

Appl. No.:

17/811026

Inventors:

- Northvale NJ, US
Yanming ZU - Tenafly NJ, US
Tahseen A. CHOWDHURY - Township of Washington NJ, US
Mohammed Irfan SYED - Dumont NJ, US

International Classification:

A61K 31/4025
A61K 47/38
A61K 9/00
A61K 47/32
A61K 47/36
A61K 47/26

Abstract:

The present disclosure relates to an oral eliglustat transmucosal delivery system. More specifically, the present disclosure is related to an oral transmucosal dosage form comprising a non-disintegrating solid mass comprising (a) a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater, (b) a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons and (c) not more than 70 mg eliglustat, wherein the dosage form is 500 mg or less and provides an oral cavity residence time of at least about 5 minutes, and wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec share rate. The dosage forms of as described herein have at least 30% dose reduction as compared to commercially available eliglustat capsules. In addition, unlike the dosing prerequisite for commercially available eliglustat capsules, the oral eliglustat transmucosal dosage form described herein can be administered to patients with Gaucher disease type 1 without pre-determination of patients' CYP2D6 genotype.

US Patent:

20210379090, Dec 9, 2021

Filed:

Jun 7, 2021

Appl. No.:

17/340862

Inventors:

- Northvale NJ, US
Yanming ZU - Tenafly NJ, US
Hetalben PRAJAPATI - Dumont NJ, US
Mohammed I. SYED - Dumont NJ, US
Tahseen A. CHOWDHURY - Township Of Washington NJ, US

International Classification:

A61K 31/675
A61K 9/48
A61K 9/00

Abstract:

The present disclosure provides a remdesivir oral delivery system bypassing the first pass hepatic metabolism. More specifically, the disclosure relates to an oral dosage form of remdesivir comprising a lipid based vehicle in an enteric capsule designed to be delivered at intestine to be absorbed by lymphatic pathway, therefore minimizing the first pass hepatic metabolism and improving the oral bioavailability. In some embodiments, the disclosure provides an oral dosage form comprising: (a) remdesivir; (b) a lipid-based vehicle comprising a lipophilic vehicle, an amphiphilic vehicle, a none-aqueous hydrophilic vehicle, or combinations thereof; and (c) an enteric capsule; wherein the remdesivir is dissolved or dispersed in the lipid-based vehicle; and, wherein the remdesivir and the lipid-based vehicle are in the enteric capsule. It also relates to methods of designing and making this dosage form, and methods of usage of this dosage form in the early treatment and prophylaxis of coronavirus infections, e.g., COVID-19.

US Patent:

20190388392, Dec 26, 2019

Filed:

Jun 7, 2019

Appl. No.:

16/435071

Inventors:

- Northvale NJ, US
Yanming ZU - Tenafly NJ, US
Tahseen A. CHOWDHURY - Township of Washington NJ, US
Mohammed Irfan SYED - Dumont NJ, US

International Classification:

A61K 31/4025
A61K 47/38
A61K 9/00
A61K 47/26
A61K 47/36
A61K 47/32

Abstract:

The present disclosure relates to an oral eliglustat transmucosal delivery system. More specifically, the present disclosure is related to an oral transmucosal dosage form comprising a non-disintegrating solid mass comprising (a) a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater, (b) a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons and (c) not more than 70 mg eliglustat, wherein the dosage form is 500 mg or less and provides an oral cavity residence time of at least about 5 minutes, and wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec share rate. The dosage forms of as described herein have at least 30% dose reduction as compared to commercially available eliglustat capsules. In addition, unlike the dosing prerequisite for commercially available eliglustat capsules, the oral eliglustat transmucosal dosage form described herein can be administered to patients with Gaucher disease type 1 without pre-determination of patients' CYP2D6 genotype.